posted by AHIP
on April 9, 2019
On April 9, 2019, AHIP addressed a letter to leaders of the House Ways and Means Committee, expressing support for key provisions of H.R. 2113, the “Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act.” This bill is on the agenda for the committee’s April 9 markup.
Our letter emphasizes that requiring greater transparency is an important step to ensure that consumers have the information they need to make informed health care decisions. We explain: “Currently, many patients lack drug pricing information that helps them make informed choices about their treatment. Increasing access to pricing information can enable patients to compare different treatment options and help them find lower cost, but equally effective, choices such as generic drugs or biosimilars.”
We express support for legislative provisions in three areas: